Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Other Operating Expenses (2021 - 2025)

Macrogenics (MGNX) has disclosed Other Operating Expenses for 7 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 84.23% to $10.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.0 million, a 192.78% increase, with the full-year FY2025 number at $36.0 million, up 192.78% from a year prior.
  • Other Operating Expenses was $10.1 million for Q4 2025 at Macrogenics, down from $11.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $11.6 million in Q3 2025 to a low of $17000.0 in Q1 2021.
  • A 5-year average of $3.3 million and a median of $2.3 million in 2022 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 10818.18% in 2022, then plummeted 90.9% in 2023.
  • Macrogenics' Other Operating Expenses stood at $947000.0 in 2021, then surged by 89.12% to $1.8 million in 2022, then tumbled by 90.9% to $163000.0 in 2023, then skyrocketed by 3268.1% to $5.5 million in 2024, then surged by 84.23% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Other Operating Expenses are $10.1 million (Q4 2025), $11.6 million (Q3 2025), and $8.9 million (Q2 2025).